ImmunityBio Completes ANKTIVAs Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71 percent with a Durable Duration of Response Ranging Up to 54 Months
IBRX Stock | USD 3.15 1.49 32.11% |
Slightly above 63% of all Immunitybio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Immunitybio suggests that some traders are interested. Immunitybio's investing sentiment can be driven by a variety of factors including economic data, Immunitybio's earnings reports, geopolitical events, and overall market trends.
Immunitybio |
ImmunityBio, Inc. , a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of Novem
Read at businesswire.com
Immunitybio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Immunitybio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immunitybio Fundamental Analysis
We analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Immunitybio is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Immunitybio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunitybio stock to make a market-neutral strategy. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics with similar companies.
Peers
Immunitybio Related Equities
LXRX | Lexicon Pharmaceuticals | 21.90 | ||||
XFOR | X4 Pharmaceuticals | 13.54 | ||||
VKTX | Viking Therapeutics | 2.84 | ||||
CVAC | CureVac NV | 1.87 | ||||
ARDX | Ardelyx | 0.95 | ||||
KRYS | Krystal Biotech | 0.74 | ||||
TGTX | TG Therapeutics | 0.06 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
MDGL | Madrigal Pharmaceuticals | 1.99 | ||||
PDSB | PDS Biotechnology | 2.80 | ||||
MCRB | Seres Therapeutics | 3.23 | ||||
VIR | Vir Biotechnology | 3.34 | ||||
ELEV | Elevation Oncology | 4.00 | ||||
BLRX | BioLineRx | 4.00 |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.